ClinicalTrials.gg
RecruitingNCT02864108HTPUpdated Oct 24, 2025

The Human Trisome Project

An observational study in Down Syndrome and Trisomy 21, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 6 Months to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by University of Colorado, Denver · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
6 Months to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Down Syndrome by University of Colorado, Denver — 4 open to participants now, 4 under way, 1 of them phase 3. Down Syndrome · University of Colorado, Denver.

Started
2016
with 1 other
Observational
5 of 12
2 open now
Registered
5th of 12
by date

Among the 12 studies in Down Syndrome by University of Colorado, Denver, this one is one of 2 that started in 2016, is one of 5 observational ones, and was the 5th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

4 of the 12 studies in Down Syndrome by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 6 Months to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Down Syndrome by University of Colorado, Denver, or all of them as a file.
02

Study summary

The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.

Read the detailed description

The purpose of this study is to provide qualified and approved researchers with access to biological samples and health information to answer specific research questions. This project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions such as Alzheimer's disease, congenital heart defects, autoimmune disorders, autism, and some forms of leukemia.

Participation includes a blood draw, a mouth swab, and allowing researchers to look at your health information yearly for the next 5 years. Optional procedures include providing a urine and/or stool sample and taking part in the study for a longer time frame.

03

Conditions studied

  • Down Syndrome
  • Trisomy 21

Browse trials for

04

Who can participate

Ages eligible
6 Months to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals with Down syndrome, individuals related to someone with Down syndrome or of the general population who do not have a relationship to Down syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Anyone 6 months to 89 years old who:

  1. has Down syndrome (any type)
  2. does not have Down syndrome

Exclusion criteria

Exclusion Criteria:

  1. Prisoners
  2. Wards of the state
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Those with trisomy 21

    People aged 6 months to 89 years old who have some form of trisomy 21.

  • Controls

    People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.

06

What researchers measure

Primary outcomes

  1. Number of Participants and Controls Enrolled in Biobank

    Create biobank of blood cells and plasma, saliva, mouth swab, urine, stool, and induced pluripotent stem cells (iPSC) cells for use in approved research projects.

    Time frame: 5 years

Secondary outcomes

  1. Number of Clinical Records Available for Approved Research Purposes

    Create a database of clinical information to pair with biological samples listed above.

    Time frame: 5 years

  2. Multidimensional Sample Characterization

    Characterize biological samples with multidimensional cellular and molecular analyses to generate the most thoroughly characterized set of samples from individuals with Down syndrome in the world.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
    Denver, Colorado 80045, United States
    Recruiting
    • Joaquin Espinosa, PhD · Principal investigator
08

References and documents

Publications

  • Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, Khanal S, Butcher ET, Estrada BE, Rachubinski AL, McWilliams JA, Minter R, Dimasi T, Colvin KL, Baturin D, Pham AT, Galbraith MD, Bartsch KW, Yeager ME, Porter CC, Sullivan KD, Hsieh EW, Espinosa JM. Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. Cell Rep. 2019 Nov 12;29(7):1893-1908.e4. doi: 10.1016/j.celrep.2019.10.038. PubMed 31722205 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jul 2036 and a completion of Jul 2036. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2016
First posted
Aug 11, 2016
Start
Jul 2016
Primary completionEst.
Jul 2036
CompletionEst.
Jul 2036
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02864108
Collaborators
Linda Crnic Institute for Down Syndrome, National Center for Advancing Translational Sciences (NCATS), GLOBAL Down Syndrome Foundation, Anna and John J. Sie Foundation
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Jul 2016
Primary completion
Jul 2036 (estimated)
Completion
Jul 2036 (estimated)
Last update
Oct 24, 2025

Study contacts

Angela Rachubinski, PhD
Contact
dsresearch@cuanschutz.edu
(303) 724-7366
Constance Brecl, BA
Contact
dsresearch@cuanschutz.edu
Joaquin Espinosa, PhD
principal investigator · Linda Crnic Institute for Down Syndrome at the University of Colorado Denver
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion